Trevi Therapeutics Income Statement (2018-2026) | TRVI

Income Statement Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating items
Research & Development (Quarter)
6.50M4.72M6.18M4.64M5.10M5.77M4.32M5.00M5.84M6.32M6.52M8.80M10.02M11.22M9.33M9.39M10.09M6.19M
Selling, General & Administrative (Quarter)
2.67M2.23M2.09M2.38M2.72M2.64M2.34M2.56M2.54M2.72M2.42M3.10M3.27M2.86M2.92M4.33M3.83M4.03M
Operating Expenses (Quarter)
9.17M6.95M8.27M7.03M7.82M8.40M6.66M7.56M8.38M9.04M8.93M11.91M13.29M14.09M12.24M13.72M13.92M10.22M
Operating Income (Quarter)
-9.17M-6.95M-8.27M-7.03M-7.82M-8.40M-6.66M-7.56M-8.38M-9.04M-8.93M-11.91M-13.29M-14.09M-12.24M-13.72M-13.92M-10.22M
EBIT (Quarter)
-9.17M-6.95M-8.27M-7.03M-7.82M-8.40M-6.66M-7.56M-8.38M-9.04M-8.93M-11.91M-13.29M-14.09M-12.24M-10.35M-13.72M-13.92M-10.22M-13.21M
Non-operating items
Interest & Investment Income (Quarter)
0.00M0.00M0.00M0.00M0.20M0.42M1.12M1.22M1.21M1.18M1.14M1.00M0.94M0.83M0.84M1.41M2.10M1.90M
Other Non Operating Income (Quarter)
0.04M-0.01M-0.40M-0.01M-0.14M0.17M0.15M0.15M-0.00M-0.00M-0.01M-0.01M0.00M-0.01M-0.00M-0.01M
Non Operating Income (Quarter)
-0.63M-0.31M-0.25M-0.31M-0.24M0.13M0.70M0.17M0.15M1.33M4.35M1.00M0.93M-0.01M-2.75M-0.01M2.10M6.52M
Net income details
EBT (Quarter)
-9.80M-7.25M-8.53M-7.33M-8.06M-8.27M-5.53M-6.41M-7.17M-7.71M-7.80M-10.91M-12.36M-13.27M-11.40M-10.35M-12.32M-11.82M-8.33M-13.21M
Tax Provisions (Quarter)
-0.00M0.00M-0.01M-0.01M-0.00M-0.01M-0.02M-0.01M-0.03M-0.01M0.02M-0.01M-0.01M-0.03M0.02M-0.01M-0.02M-0.01M-0.02M-0.02M
Profit After Tax (Quarter)
-9.79M-7.25M-8.48M-7.33M-8.05M-8.27M-5.50M-6.40M-7.14M-7.70M-7.82M-10.90M-12.35M-13.24M-11.41M-10.34M-12.30M-11.80M-8.32M-13.19M
Income from Continuing Operations (Quarter)
-9.79M-7.25M-8.52M-7.33M-8.05M-8.27M-5.50M-6.40M-7.14M-7.70M-7.82M-10.90M-12.35M-13.24M-11.41M-10.34M-12.30M-11.80M-8.32M-13.19M
Consolidated Net Income (Quarter)
-9.79M-7.25M-8.52M-7.33M-8.05M-8.27M-5.50M-6.40M-7.14M-7.70M-7.82M-10.90M-12.35M-13.24M-11.41M-10.34M-12.30M-11.80M-8.32M-13.19M
Income towards Parent Company (Quarter)
-9.79M-7.25M-8.52M-7.33M-8.05M-8.27M-5.50M-6.40M-7.14M-7.70M-7.82M-10.90M-12.35M-13.24M-11.41M-10.34M-12.30M-11.80M-8.32M-13.19M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-9.79M-7.25M-8.52M-7.33M-8.05M-8.27M-5.50M-6.40M-7.14M-7.70M-7.82M-10.90M-12.35M-13.24M-11.41M-10.34M-12.30M-11.80M-8.32M-13.19M
Additional items
EPS (Basic) (Quarter)
-0.49-0.34-0.24-0.24-0.14-0.12-0.01-0.06-0.07-0.08-0.08-0.11-0.12-0.13-0.11-0.09-0.09-0.08-0.06-0.09
EPS (Weighted Average and Diluted) (Quarter)
-0.49-0.34-0.24-0.24-0.14-0.12-0.01-0.06-0.07-0.08-0.08-0.11-0.12-0.13-0.11-0.09-0.09-0.08-0.06-0.09
Shares Outstanding (Weighted Average) (Quarter)
19.77M21.61M22.84M30.81M45.25M53.22M64.54M98.61M98.70M99.33M99.03M99.52M101.04M101.28M101.97M117.61M124.02M131.12M134.75M145.59M
Shares Outstanding (Diluted Average) (Quarter)
19.77M21.61M22.84M30.81M45.25M68.90M64.54M98.61M98.70M98.88M99.03M99.52M100.28M101.28M101.97M117.61M130.35M145.10M134.75M145.59M
EBITDA (Quarter)
-9.79M-7.25M-8.27M-7.03M-8.19M-8.39M-6.66M-7.56M-8.38M-9.04M-8.93M-11.91M-13.29M-14.09M-12.24M-10.33M-13.72M-13.92M-10.22M-13.53M
Interest Expenses (Quarter)
0.38M0.30M0.83M0.30M0.29M0.29M0.27M0.23M0.15M0.00M0.00M0.00M0.00M0.00M0.00M
Tax Rate (Quarter)
0.02%-0.03%0.07%0.07%0.05%0.08%0.36%0.11%0.42%0.17%-0.23%0.07%0.06%0.23%-0.14%0.11%0.17%0.13%0.19%0.15%